Well, a trial is not about the molecular mechanisms of a drug. It is about checking whether a drug works and whether it is better than existing drugs. So statistics.
Still hard, obviously, and plenty of space for semantic whitewashing.
A trial usually tries to justify a mechanism of action. That's the least you try to do when you spend hundred of USD millions in a Phase 2 or 3 trial. And anyway even if a drug works better than another, it's almost never a black and white result, because drug safety profile usualy differ. You'll end p with a one pager result most laymen won't be able to grasp, no matter how you want to simplify things.
Comments
Well, a trial is not about the molecular mechanisms of a drug. It is about checking whether a drug works and whether it is better than existing drugs. So statistics.
Still hard, obviously, and plenty of space for semantic whitewashing.
A trial usually tries to justify a mechanism of action. That's the least you try to do when you spend hundred of USD millions in a Phase 2 or 3 trial. And anyway even if a drug works better than another, it's almost never a black and white result, because drug safety profile usualy differ. You'll end p with a one pager result most laymen won't be able to grasp, no matter how you want to simplify things.